No impact of omega-3 fatty acid supplementation on symptoms or hostility among patients with schizophrenia

In this double-blind, placebo-controlled trial, Qiao et al. (2020) investigated the impact of administering fish oil (omega-3 fatty acids) supplements on the hostility and psychopathology among patients with acute violent schizophrenia. The participants were acute hospitalized patients showing violent behavior attributed to their schizophrenia, and who were being treated with antipsychotics. Thirty-two patients were given the fish oil supplement while 35 were treated with placebo as a result of random allocation. Assessments were conducted at baseline, week 4 and week 8. Reductions in symptoms and hostility were reported after treatment at the 4-week and 8-week marks for both groups, with no variation between the fish oil intervention and placebo. This data implies that omega-3 fatty acids do not reduce psychopathology nor hostility in acute patients with schizophrenia. [NPID: mood disorders, psychiatric disorders, fish oil, omega-3 fatty acids, schizophrenia]

Year: 2020

Reference: Qiao, Y., Liu, C. P., Han, H. Q., Liu, F. J., Shao, Y., & Xie, B. (2020). No Impact of Omega-3 Fatty Acid Supplementation on Symptoms or Hostility Among Patients With Schizophrenia. Frontiers in psychiatry, 11, 312. https://doi.org/10.3389/fpsyt.2020.00312

Related Studies

High-sucrose diets contribute to brain angiopathy with impaired glucose uptake and psychosis-related higher brain dysfunctions in mice

This 2021 animal study was designed to test the effects of high-sucrose diets on mice lacking an enzyme called glyoxalase-1 (GLO1). The results demonstrated that a high-sucrose diet during adolescence induced psychosis-related behavioral factors such as hyperactivity and poor working memory. Following the intake of the high-sucrose diet, the researchers observed impairments in microcapillaries and […]

Ketogenic Diet intervention on metabolic and psychiatric health in Bipolar and Schizophrenia: A pilot trial

The ketogenic diet (KD), also referred to as metabolic therapy, has demonstrated efficacy in addressing conditions such as type 2 diabetes, obesity, and epilepsy. Recently, KD has emerged as a promising treatment for psychiatric disorders. We conducted a four-month pilot study to explore the impact of KD on individuals with schizophrenia or bipolar disorder who […]